Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1858 participants.

Also called NCT02814409

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,858 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02814409
Other papers using this trial's data
  • Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial The Lancet. Neurology, 2024-11 DOI, PubMed 39424558

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02814409. Randomized; no masking; primary purpose treatment. Start 2016-12-15 (actual); primary completion 2023-08-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis
Acronym
ATTEST2
Intervention (Drug)
Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase
Intervention (Drug)
Intravenous Tenecteplase
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)
Collaborator
University of Edinburgh (class: other)
Collaborator
Oxford University Hospitals NHS Trust (class: other)

Record details

Record id
cardio:ct-nct02814409
Content hash
42154b17797701ef4a1b090435a34752f6c7144fbaffad757ef9de4799456ec2